Mcp- Sf (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide blocks dopamine D2 receptors in the brain’s chemoreceptor trigger zone, reducing nausea signals, while stimulating muscarinic receptors in the gastrointestinal tract to increase motility. This dual action helps suppress vomiting and promotes faster gastric emptying.

The dosage of Mcp- Sf is determined by the prescribing clinician based on the patient’s condition, severity, and route of administration. Healthcare professionals adjust the amount and frequency to achieve the desired therapeutic effect while minimizing risk.

Safety of metoclopramide in pregnancy or while breastfeeding has not been definitively established. Clinicians weigh potential benefits against possible risks and may limit use to situations where the expected benefit justifies exposure.

To request Mcp- Sf, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoclopramide differs from many antiemetics by also enhancing gastrointestinal motility, whereas agents like ondansetron act primarily on serotonin receptors. For patients with delayed gastric emptying, metoclopramide offers the added benefit of pro‑kinetic activity, but it carries a distinct side‑effect profile that must be considered.

Mcp- Sf should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures to maintain stability and potency.

Mcp- Sf is supplied as an injectable solution for intramuscular or intravenous administration. The route, rate and site of injection are selected by the healthcare professional according to the clinical indication and patient needs.

Serious risks include extrapyramidal reactions such as dystonia, tardive dyskinesia—a potentially irreversible movement disorder—and neuroleptic malignant syndrome, a rare but life‑threatening condition characterized by fever, muscle rigidity and autonomic instability.

Metoclopramide is contraindicated in individuals with known hypersensitivity to the drug, those with pheochromocytoma, and patients with a history of seizure disorders or severe depression. It should also be avoided in infants under one month of age.